SARS (severe acute respiratory syndrome) diagnosis and patenting, a story of two wars
This article was originally published in Clinica
Executive Summary
Prompt diagnosis has emerged as the key priority of the war against severe acute respiratory syndrome (SARS), after mortality from the disease in China has soared to three times the World Health Organization's upgraded global rate of 7%. Meanwhile, manufacturers and public health bodies alike have become embroiled in a battle of their own to secure patenting rights over the virus.